Impact of body mass index on clinico-pathological parameters and outcome in patients with metastatic prostate cancer

Background: This study evaluates the correlation between body mass index (BMI) and clinicopathological parameters of metastatic prostate cancer (MPC) and its impact on survival. Method: During the study period, 71 MPC patients were eligible. Patients with BMI < 25.0 kg/m2 were categorized as leve...

Full description

Bibliographic Details
Main Authors: Amrallah A. Mohammed, Hani EL-Tanni, Hafez M. Ghanem, Mian U. Farooq, Amr M. El Saify, Abdullah S. Al-Zahrani, Ayman EL-Shentenawy, Hani M. EL-Khatib
Format: Article
Language:English
Published: SpringerOpen 2015-09-01
Series:Journal of the Egyptian National Cancer Institute
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S111003621500059X
id doaj-d46a28a70977407b9da6b12ff0a3a304
record_format Article
spelling doaj-d46a28a70977407b9da6b12ff0a3a3042020-11-25T02:01:36ZengSpringerOpenJournal of the Egyptian National Cancer Institute1110-03622015-09-0127315515910.1016/j.jnci.2015.07.001Impact of body mass index on clinico-pathological parameters and outcome in patients with metastatic prostate cancerAmrallah A. Mohammed0Hani EL-Tanni1Hafez M. Ghanem2Mian U. Farooq3Amr M. El Saify4Abdullah S. Al-Zahrani5Ayman EL-Shentenawy6Hani M. EL-Khatib7Oncology Center, King Abdullah Medical City-Holy Capital, Saudi ArabiaOncology Center, King Abdullah Medical City-Holy Capital, Saudi ArabiaOncology Center, King Abdullah Medical City-Holy Capital, Saudi ArabiaStrategic Planning Department, King Abdullah Medical City-Holy Capital, Saudi ArabiaOncology Center, King Abdullah Medical City-Holy Capital, Saudi ArabiaOncology Center, King Abdullah Medical City-Holy Capital, Saudi ArabiaClinical Oncology Department, Faculty of Medicine, Cairo University, EgyptOncology Center, King Abdullah Medical City-Holy Capital, Saudi ArabiaBackground: This study evaluates the correlation between body mass index (BMI) and clinicopathological parameters of metastatic prostate cancer (MPC) and its impact on survival. Method: During the study period, 71 MPC patients were eligible. Patients with BMI < 25.0 kg/m2 were categorized as level I and patients with BMI ⩾ 25.0 kg/m2 were categorized as level II. Demographic features and survival rates were evaluated by the Kaplan–Meier method and Cox proportional models. Results: 31 patients belonged to level I while the rest belonged to level II with insignificant higher median follow-up duration in level II; p = 0.5. In terms of age, metastasis, serum level of albumin, prostatic specific antigen, alkaline phosphatase (AKP) and Gleason score, there was no significant difference between the two levels. The cumulative survival probability in the 12th, 24th and 36th month in level I vs; level II was; 86.7%, 68.7%, 64.1% vs; 74.4%, 67.7%, 55.1%, respectively with 7 patients dead in level I compared to 14 patients dead in level II denoting a higher PC-specific death rate in the level II group. In univariate and multivariate analysis, poor prognosis was associated with increasing AKP (HR = 1.0005, 95% CI, p = 0.03; HR = 1.001, 95% CI, p = 0.03) respectively, while better prognosis was associated with no visceral metastasis (HR = 0.09, 95% CI, p = 0.000; HR = 0.04, 95% CI, p = 0.000) and increasing albumin levels (HR = 0.17, 95% CI, p = 0.000; HR = 0.15, 95% CI, p = 0.000) respectively. In multivariate analysis only, patients belonging to level I were associated with better prognosis (HR = 0.17, 95% CI, p = 0.02). Conclusion: BMI is dependent on prognostic factors in patients with MPC.http://www.sciencedirect.com/science/article/pii/S111003621500059XCancer specific survivalMetastatic prostate cancerObesity
collection DOAJ
language English
format Article
sources DOAJ
author Amrallah A. Mohammed
Hani EL-Tanni
Hafez M. Ghanem
Mian U. Farooq
Amr M. El Saify
Abdullah S. Al-Zahrani
Ayman EL-Shentenawy
Hani M. EL-Khatib
spellingShingle Amrallah A. Mohammed
Hani EL-Tanni
Hafez M. Ghanem
Mian U. Farooq
Amr M. El Saify
Abdullah S. Al-Zahrani
Ayman EL-Shentenawy
Hani M. EL-Khatib
Impact of body mass index on clinico-pathological parameters and outcome in patients with metastatic prostate cancer
Journal of the Egyptian National Cancer Institute
Cancer specific survival
Metastatic prostate cancer
Obesity
author_facet Amrallah A. Mohammed
Hani EL-Tanni
Hafez M. Ghanem
Mian U. Farooq
Amr M. El Saify
Abdullah S. Al-Zahrani
Ayman EL-Shentenawy
Hani M. EL-Khatib
author_sort Amrallah A. Mohammed
title Impact of body mass index on clinico-pathological parameters and outcome in patients with metastatic prostate cancer
title_short Impact of body mass index on clinico-pathological parameters and outcome in patients with metastatic prostate cancer
title_full Impact of body mass index on clinico-pathological parameters and outcome in patients with metastatic prostate cancer
title_fullStr Impact of body mass index on clinico-pathological parameters and outcome in patients with metastatic prostate cancer
title_full_unstemmed Impact of body mass index on clinico-pathological parameters and outcome in patients with metastatic prostate cancer
title_sort impact of body mass index on clinico-pathological parameters and outcome in patients with metastatic prostate cancer
publisher SpringerOpen
series Journal of the Egyptian National Cancer Institute
issn 1110-0362
publishDate 2015-09-01
description Background: This study evaluates the correlation between body mass index (BMI) and clinicopathological parameters of metastatic prostate cancer (MPC) and its impact on survival. Method: During the study period, 71 MPC patients were eligible. Patients with BMI < 25.0 kg/m2 were categorized as level I and patients with BMI ⩾ 25.0 kg/m2 were categorized as level II. Demographic features and survival rates were evaluated by the Kaplan–Meier method and Cox proportional models. Results: 31 patients belonged to level I while the rest belonged to level II with insignificant higher median follow-up duration in level II; p = 0.5. In terms of age, metastasis, serum level of albumin, prostatic specific antigen, alkaline phosphatase (AKP) and Gleason score, there was no significant difference between the two levels. The cumulative survival probability in the 12th, 24th and 36th month in level I vs; level II was; 86.7%, 68.7%, 64.1% vs; 74.4%, 67.7%, 55.1%, respectively with 7 patients dead in level I compared to 14 patients dead in level II denoting a higher PC-specific death rate in the level II group. In univariate and multivariate analysis, poor prognosis was associated with increasing AKP (HR = 1.0005, 95% CI, p = 0.03; HR = 1.001, 95% CI, p = 0.03) respectively, while better prognosis was associated with no visceral metastasis (HR = 0.09, 95% CI, p = 0.000; HR = 0.04, 95% CI, p = 0.000) and increasing albumin levels (HR = 0.17, 95% CI, p = 0.000; HR = 0.15, 95% CI, p = 0.000) respectively. In multivariate analysis only, patients belonging to level I were associated with better prognosis (HR = 0.17, 95% CI, p = 0.02). Conclusion: BMI is dependent on prognostic factors in patients with MPC.
topic Cancer specific survival
Metastatic prostate cancer
Obesity
url http://www.sciencedirect.com/science/article/pii/S111003621500059X
work_keys_str_mv AT amrallahamohammed impactofbodymassindexonclinicopathologicalparametersandoutcomeinpatientswithmetastaticprostatecancer
AT hanieltanni impactofbodymassindexonclinicopathologicalparametersandoutcomeinpatientswithmetastaticprostatecancer
AT hafezmghanem impactofbodymassindexonclinicopathologicalparametersandoutcomeinpatientswithmetastaticprostatecancer
AT mianufarooq impactofbodymassindexonclinicopathologicalparametersandoutcomeinpatientswithmetastaticprostatecancer
AT amrmelsaify impactofbodymassindexonclinicopathologicalparametersandoutcomeinpatientswithmetastaticprostatecancer
AT abdullahsalzahrani impactofbodymassindexonclinicopathologicalparametersandoutcomeinpatientswithmetastaticprostatecancer
AT aymanelshentenawy impactofbodymassindexonclinicopathologicalparametersandoutcomeinpatientswithmetastaticprostatecancer
AT hanimelkhatib impactofbodymassindexonclinicopathologicalparametersandoutcomeinpatientswithmetastaticprostatecancer
_version_ 1724956755269517312